Skip to Content

Adderall XR approved in three new strengths

BASINGSTOKE, U.K. -- Shire Pharmaceuticals Group announced that it has received U.S. Food and Drug Administration (FDA) approval for three further strengths of Adderall XR, its once a day treatment for Attention Deficit Hyperactivity Disorder (ADHD).

Adderall XR is a once-daily extended release capsule containing mixed salts of a single entity amphetamine product; dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate and amphetamine aspartate monohydrate. The Adderall XR capsule contains two types of drug containing beads designed to give a double-pulsed delivery of amphetamines, which prolongs the release of amphetamine from Adderall XR compared to the conventional Adderall (immediate release) tablet formulation. 

The newly approved 5, 15 and 25mg capsules complement the existing 10, 20 and 30mg capsules to provide doctors with significant flexibility to individually tailor the dosing to each patient's needs.

With this wider range now available patients converting from Adderall to Adderall XR will be able to change more easily from their existing daily dose to the convenient and effective once a day Adderall XR capsule.

Rolf Stahel, Chief Executive of Shire, said: "The availability of a full complement of strengths for Adderall XR furthers our goal to provide doctors and their ADHD patients with effective treatments that suit their needs and lifestyles.

"Our continuing commitment to securing a strong long-term and global presence in this important and expanding disease area includes work to extend the licence for Adderall XR to enable its use in adults with ADHD, together with developing new non scheduled treatments for both children and adults."

Posted: June 2002